In non-small cell lung cancer (NSCLC), J2 compound that is highly cross-linked to HSP27, sensitized HSP27 highly expressing lung cancer cells to HSP90 inhibitors, taxol, and cisplatin [248]. Here, HSPB1 is linked to lung carcinoma.